Staphylococcal Infection
13
0
0
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
31%
4 trials in Phase 3/4
58%
7 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (13)
Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73
Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA)
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial